Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | HOOK |
---|---|---|
09:32 ET | 22085 | 0.834 |
09:34 ET | 9700 | 0.829899 |
09:36 ET | 1767 | 0.82 |
09:38 ET | 2116 | 0.8364 |
09:39 ET | 130 | 0.8298 |
09:41 ET | 12596 | 0.82 |
09:43 ET | 186 | 0.820001 |
09:45 ET | 9799 | 0.839003 |
09:48 ET | 174 | 0.82 |
09:52 ET | 400 | 0.825 |
09:54 ET | 22064 | 0.837 |
09:56 ET | 2649 | 0.836691 |
09:57 ET | 1500 | 0.834051 |
10:01 ET | 23960 | 0.84 |
10:03 ET | 15986 | 0.86 |
10:06 ET | 82805 | 0.855 |
10:08 ET | 3400 | 0.8691 |
10:10 ET | 4031 | 0.868 |
10:12 ET | 7000 | 0.8601 |
10:14 ET | 2300 | 0.862001 |
10:17 ET | 3800 | 0.8692 |
10:19 ET | 22123 | 0.87 |
10:21 ET | 13214 | 0.8701 |
10:24 ET | 16799 | 0.8895 |
10:26 ET | 800 | 0.884 |
10:28 ET | 9789 | 0.899 |
10:30 ET | 18206 | 0.8812 |
10:32 ET | 10860 | 0.885549 |
10:33 ET | 1600 | 0.88 |
10:35 ET | 2800 | 0.88 |
10:39 ET | 29722 | 0.89 |
10:42 ET | 7551 | 0.89 |
10:44 ET | 95409 | 0.8945 |
10:46 ET | 69659 | 0.9 |
10:48 ET | 14330 | 0.909 |
10:50 ET | 12241 | 0.909 |
10:51 ET | 9600 | 0.9009 |
10:53 ET | 1555 | 0.892 |
10:55 ET | 13053 | 0.88001 |
10:57 ET | 1124 | 0.88 |
11:00 ET | 190 | 0.872301 |
11:02 ET | 6800 | 0.885 |
11:04 ET | 1300 | 0.8722 |
11:06 ET | 3000 | 0.8897 |
11:08 ET | 1000 | 0.8894 |
11:09 ET | 500 | 0.88 |
11:11 ET | 10462 | 0.855 |
11:13 ET | 2399 | 0.8549 |
11:15 ET | 1596 | 0.8591 |
11:18 ET | 100 | 0.8601 |
11:22 ET | 1100 | 0.859 |
11:24 ET | 1255 | 0.865 |
11:27 ET | 125 | 0.87 |
11:36 ET | 100 | 0.8551 |
11:38 ET | 100 | 0.8551 |
11:44 ET | 500 | 0.8551 |
11:45 ET | 1185 | 0.8685 |
11:56 ET | 200 | 0.8649 |
11:58 ET | 380 | 0.87 |
12:02 ET | 500 | 0.865 |
12:03 ET | 100 | 0.8655 |
12:05 ET | 100 | 0.8611 |
12:07 ET | 21547 | 0.8646 |
12:09 ET | 575 | 0.865 |
12:16 ET | 800 | 0.86 |
12:18 ET | 220 | 0.86 |
12:20 ET | 1300 | 0.8649 |
12:21 ET | 200 | 0.86 |
12:25 ET | 13600 | 0.855 |
12:32 ET | 132 | 0.85 |
12:34 ET | 500 | 0.86 |
12:36 ET | 400 | 0.855001 |
12:38 ET | 300 | 0.8501 |
12:41 ET | 100 | 0.8501 |
12:43 ET | 147 | 0.8575 |
12:45 ET | 6012 | 0.8632 |
12:48 ET | 3400 | 0.865 |
12:50 ET | 5377 | 0.8725 |
12:52 ET | 3700 | 0.875 |
12:54 ET | 400 | 0.8725 |
12:56 ET | 10452 | 0.8725 |
12:59 ET | 200 | 0.8577 |
01:03 ET | 100 | 0.8747 |
01:10 ET | 603 | 0.854 |
01:12 ET | 2654 | 0.850655 |
01:15 ET | 2699 | 0.85 |
01:32 ET | 11323 | 0.8545 |
01:42 ET | 2522 | 0.865 |
01:46 ET | 100 | 0.865 |
01:48 ET | 190 | 0.8553 |
01:51 ET | 200 | 0.8519 |
02:06 ET | 136 | 0.8599 |
02:11 ET | 596 | 0.86 |
02:13 ET | 500 | 0.8649 |
02:18 ET | 1100 | 0.856 |
02:22 ET | 700 | 0.8649 |
02:26 ET | 600 | 0.856 |
02:27 ET | 100 | 0.86 |
02:31 ET | 5400 | 0.8605 |
02:33 ET | 1050 | 0.86 |
02:38 ET | 240 | 0.86 |
02:40 ET | 250 | 0.86 |
02:42 ET | 100 | 0.86 |
02:45 ET | 10900 | 0.87075 |
02:51 ET | 5600 | 0.885 |
02:54 ET | 1150 | 0.884499 |
02:56 ET | 300 | 0.8845 |
02:58 ET | 700 | 0.87975 |
03:00 ET | 1800 | 0.877499 |
03:02 ET | 5185 | 0.875 |
03:03 ET | 100 | 0.875 |
03:07 ET | 300 | 0.8815 |
03:16 ET | 126 | 0.8814 |
03:20 ET | 5700 | 0.88 |
03:23 ET | 1300 | 0.8788 |
03:27 ET | 2127 | 0.8686 |
03:32 ET | 700 | 0.8685 |
03:34 ET | 3140 | 0.86 |
03:36 ET | 2700 | 0.8646 |
03:38 ET | 12700 | 0.8602 |
03:39 ET | 4000 | 0.865099 |
03:41 ET | 200 | 0.8602 |
03:43 ET | 945 | 0.87 |
03:45 ET | 3800 | 0.8644 |
03:50 ET | 10500 | 0.8644 |
03:52 ET | 1713 | 0.865 |
03:54 ET | 8380 | 0.869 |
03:56 ET | 505 | 0.8651 |
03:57 ET | 655 | 0.869 |
03:59 ET | 13508 | 0.869 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
HOOKIPA Pharma Inc | 78.6M | 0.0x | --- |
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which is designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. The Company’s replicating and non-replicating technologies are engineered to induce durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. Its oncology programs include HB-200 and HB-700, all of which use its replicating technology. HB-200 is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) cancers in a Phase I/II clinical trial. HB-700 is in preclinical development for the treatment of KRAS mutated cancers, including lung, colorectal and pancreatic cancers. Its Hepatitis B (HBV) program, HB-400, and its Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in a partnership with Gilead Sciences, Inc.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $78.6M |
---|---|
Revenue (TTM) | $53.6M |
Shares Outstanding | 99.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.75 |
EPS | $-0.59 |
Book Value | $0.91 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 1.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -119.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.